AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC

NCT06196814 ↗

Phase 1/2 Not yet recruiting 150 enrolled Hunan Province Tumor Hospital

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The investigators want to evaluated the Efficay and Satety of PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC who Failed from First-Line Standard Treatment.

Timeline

Start: 2024-10-01
Primary completion: 2026-03-01
Completion: 2027-02-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ivonescimab	Monoclonal antibody	20 mg	—
Subject	Ivonescimab	Monoclonal antibody	30 mg	—

Indications

No indication recorded.